Aileron gains on new early-stage data from chemoprotective drug study

Rein Therapeutics

26/10/2022 12:00

** Shares of drug developer Aileron Therapeutics  ALRN.O 
rise ~8% to 22 cents before the bell
    ** ALRN presents new data from an early-stage trial, showing
its drug candidate ALRN-6924 can help in preventing certain side
effects of chemotherapy including anemia and hair loss
 urn:newsml:reuters.com:*:nGNX49SffM
    ** Co says data confirms longer duration of effect for
ALRN-6924 at higher doses, supporting dose selection in an
ongoing trial of the drug in patients with breast cancer 
    ** ALRN presented data at the 2022 EORTC-NCI-AACR
International Conference on Molecular Targets and Cancer
Therapeutics 
    ** As of last close, BSX down ~63% YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))